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Abstract. – OBJECTIVE: There is a gap in 
the knowledge concerning oral anticoagula-
tion (OAC) in atrial fibrillation (AF) patients with 
a non-high risk of stroke. CHA2DS2VASc and 
CHADS2 scores generated imprecise risk esti-
mates for low risk patients. We aimed to assess 
OAC in patients with low risk by CHADS2 and re-
classified as high-risk by CHA2DS2VASc.
PATIENTS AND METHODS: In this study, retro-
spective nationwide population-based study, data 
were obtained from the Turkish claims and utiliza-
tion management system. Patients with non-val-
vular AF (n=451,113) between 2007 and 2012 
sub-divided into those with a CHA2DS2VASc≥1 
and CHADS2=0 (n=41,273) who were off-warfarin 
(n=29,448) and on-warfarin (n=11,825). Stroke and 
systemic embolism, major bleeding, all-cause 
mortality, net clinical benefit (NCB) and ultimate 
NCB (UNCB) were assessed.
RESULTS: Of the total cohort (mean age 66.1 
± 14.1 years, 56.1% female), CHA2DS2VASc im-
proved the net reclassification index of ob-
served 5-year composite thromboembolic end-
point by 6.9% (p<0.05). CHA2DS2VASc reclassi-
fied 9.7% low risk patients as high risk. Among 
reclassified-high-risk category (patients with a 
CHA2DS2VASc score of ≥1 and CHADS2 score 
of 0), major bleeding for that prescribed warfarin 
was 3% and higher than the rate of thromboem-
bolism among those off-warfarin. NCB (-0.035) 
and UNCB (-0.021) were negative. Death and 
hospitalization at 1 year were significantly high-
er for on-warfarin group.
CONCLUSIONS: Clinical outcomes, net clini-
cal benefit indices are negative; rates of death 
and hospitalization were significantly higher for 
OAC in reclassified category. This emphasizes 
the importance of greater attention to balanc-
ing the risks and benefits of OAC in patients with 
low risk by CHADS2 and reclassified as high-risk 
by CHA2DS2VASc.
Key Words: 
Anticoagulation, Atrial fibrillation, CHADS2, CHA2DS-
2VASc.
Introduction
Atrial fibrillation (AF), the most common sus-
tained clinical arrhythmia, is associated with a 
five-fold increased risk of stroke1-3. Thromboem-
bolic strokes due to AF are more disabling and 
fatal, and recurrences are more frequent than oth-
er causes of stroke2,4. Oral anticoagulants (OAC), 
such as warfarin, have been shown to be superior 
to placebo for primary and secondary prevention 
among patients at moderate-to-high risk of stroke 
when prescribed according to a calculated stroke 
risk4-7. However, warfarin is associated with a 
risk of bleeding, which must be considered in 
the management of patients with AF8. Moreover, 
there is clinical uncertainty regarding the on-war-
farin and off-warfarin effects among patients with 
AF according to the level of stroke risk. 
There is a gap in the knowledge base concern-
ing the risks of off-warfarin thromboembolism 
and on-warfarin major bleeding among patients 
who have a low risk of stroke. Stroke risk stratifi-
cation schemes, such as CHA2DS2VASc [Cardiac 
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failure, Hypertension, Age≥75 (doubled), Diabetes, 
Stroke (doubled) – Vascular disease, Age 65–74 
and Sex category (female)] and previously CHADS2 
[Cardiac failure, Hypertension, Age ≥75, Diabetes, 
Stroke (doubled)] classify patients to different risk 
groups9,10. Recent guidelines11,12 have relegated the 
role of acetylsalicylic acid for the management of 
AF and, consequently, patients of intermediate risk 
(CHADS2 or CHA2DS2VASc score =1), which con-
stitutes a large proportion of patients with AF; typi-
cally, either receive an OAC or no anticoagulant. 
The selection of low or intermediate risk pa-
tients for OAC or no anticoagulant is not straight-
forward2. The initial CHADS2 risk score was a 
pragmatic tool. Yet, it failed to identify all patients 
who were at low risk of stroke and systemic embo-
lism12. By contrast, the CHA2DS2VASc risk score 
more readily predicts stroke among lower risk pa-
tients with AF who may not justify the use of an 
OAC and is, therefore, recommended for accurate 
identification of patients who do not need antico-
agulation12. Even so, the CHA2DS2VASc risk score 
overestimates the risk of stroke among intermedi-
ate risk patients13,14. The implications of imprecise 
stroke risk prediction are huge – overestimation of 
risk may be associated with medical harm through 
inappropriate anticoagulation and underestimation 
associated with thromboembolic events associated 
with failure to prescribe an OAC. 
There are only a few large population-based 
or whole-country studies concerning off-war-
farin thromboembolism and on-warfarin ma-
jor hemorrhage according to the CHADS2 and 
current CHA2DS2VASc scores for patients with 
non-valvular AF15,16. We have established the first 
whole-country TuRkish Atrial Fibrillation (TRAF) 
cohort of individual patient data from a systemat-
ic health insurance database which covers nearly 
all 50,364,653 inhabitants over the age of 18 in the 
country3. Herein, we aimed (i) to compare former 
CHADS2 and current CHA2DS2VASc risk score 
model performance, and (ii) to report the rates of 
off-warfarin thromboembolism and on-warfarin 
major bleeding, mortality and stroke for reclassi-
fied-high risk category (patients with a CHA2DS-
2VASc score of ≥1 and CHADS2 score of 0). 
Patients and Methods
Data Source
Data for the TRAF cohort were obtained from 
the Turkish claims and utilization management 
system, MEDULA, which processes claims for 
all health insurance funds in Turkey. Covering 
close to 100% of the population, MEDULA is 
comprised of pharmacy, inpatient, outpatient and 
laboratory claims and across 23 500 pharmacies, 
20,000 general practitioners, 850 government 
hospitals, 60 university hospitals and 500 private 
hospitals3. Medical data entered into the MEDU-
LA database by physicians include patient demo-
graphics, prescription details, observed clinical 
events, outpatient clinics, inpatient hospitaliza-
tions and major clinical outcomes. For each hos-
pitalization, the dates of admission and discharge, 
main diagnoses and major outcomes are recorded. 
The MEDULA system links to the Turkish na-
tional death database, whereby information con-
cerning the date and cause of death are available. 
The TRAF cohort is formed from extracted an-
onymized patient-level data. Current study com-
plies with the Declaration of Helsinki. The study 
was approved by the Research Ethics Committee. 
All necessary permissions were obtained from 
the Social Security Institution of Turkey.
Study Population
We included all individuals with a diagnosis 
of AF (n=545,008) who were aged over 18 years 
between 1 January 2008 and 31 December 2012 
and who survived the first 30 days following their 
diagnosis of AF (Figure 1). We excluded those 
patients who died very early after a diagnosis 
of AF presumably because their death would be 
unlikely to be associated with AF. We used In-
ternational Classification of Diseases (ICD) -10 
code I48 (paroxysmal, persistent, or permanent 
AF) to identify AF. We defined patients as having 
non-valvular AF according to international guide-
lines by excluding those who had mitral stenosis 
Figure 1. Data flow for patients included in the analysis.
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or a history of valve surgery. We defined lone 
AF as those patients with non-valvular AF who 
had no comorbidity. For the analytical cohort, 
we identified 451,113 patients with a diagnosis of 
non-valvular AF during the 5-year study period. 
We used the Anatomical Therapeutic Chemical 
Classification System with Defined Daily Doses 
(ATC/DDD) Index of drug codes to identify war-
farin (B01AA03) prescriptions. During the study 
period, warfarin was the only OAC available for 
AF. The ICD-10 codes used for the diagnostic, 
co-morbidity and clinical endpoint categorizes 
are listed in Supplementary Table I. 
Clinical Endpoints
We defined two composite endpoints, throm-
boembolism [which included ischemic stroke, un-
specified stroke, transient ischemic attack (TIA) 
and systemic embolism], and International Soci-
ety on Thrombosis and Haemostasis (ISTH) ma-
jor bleeding. ISTH major bleeding was defined as 
(i) fatal bleeding and/or, (ii) symptomatic bleed-
ing in a critical area or organ, such as intracranial, 
intraspinal, intraocular, retroperitoneal, intraar-
ticular or pericardial, or intramuscular with com-
partment syndrome and/or (iii) bleeding causing a 
fall in hemoglobin level of 2 g/dL (1.24 mmol/L) 
or more; or leading to transfusion of two or more 
units of whole blood or red cells. (which included 
intracranial bleeding and any severe bleeding)17. 
We also reported, separately, rates and risks of 
ischemic stroke, and all-cause mortality at 1 year. 
We analyzed pre-defined 2 parameters, namely, 
net clinical benefit (NCB) and ultimate net clin-
ical benefit (UNCB) of warfarin therapy in AF. 
The following equations illustrates this definition: 
NCB = (Composite thromboembolism rate 
off warfarin – composite thromboembolism rate 
on warfarin) – Weight × (Major bleeding rate on 
warfarin – bleeding rate off warfarin).
UNCB = (Mortality rate off warfarin – mortal-
ity rate on warfarin) – Weight × (Major bleeding 
rate on warfarin – bleeding rate off warfarin).
The weighting factor reflects the relative im-
pact, in terms of death and disability, of intracra-
nial hemorrhage (including intracerebral, sub-
dural, subarachnoid, and other bleedings) while 
receiving warfarin vs. experiencing ultimate end-
point while not receiving warfarin18,19.
Ischemic Stroke Risk Scores
For each patient, we calculated their risk of 
ischemic stroke according to the CHADS2 score 
and the CHA2DS2VASc score
2,20. The risks of 
stroke were then categorized according to scores 
of 0: low, 1: intermediate, and ≥2: high risk. The 
components of the CHADS2 score were defined 
using ICD codes for heart failure, hypertension, 
diabetes mellitus, previous ischemic stroke, un-
specified stroke, TIA or systemic embolism and 
age at data entry. Components of the CHA2DS-
2VASc score were, in addition to these factors 
used for definition of the CHADS2 score, vascular 
disease (prior myocardial infarction, peripheral 
arterial disease) and gender. 
Table I. Baseline characteristics of the analytical cohort of patients with AF stratified by use of Warfarin.
 All On warfarin Off warfarin
 (n = 451,113) (n = 176,482) (n = 274,631) p-value
Follow-up (months) Median (IQR) 20 (8-52) 18 (8-52) 20 (10-50) 0.09
Mean (SD) age, years 66.08 (±14.14) 65.99 (±12.19) 66.14 (±15.27) 0.32
Mean (SD) CHADS2 score 2.16 (±0.002) 2.33 (±0.003) 2.05 (±0.003) < 0.001
Mean (SD) CHA2DS2VASc score 3.96 (±0.003) 4.20 (±0.004) 3.79 (±0.004) 0.89
Chronic obstructive pulmonary disease (%) 28.6 (N=129,051) 28.5 (N=50,262) 28.7 (N=78,789) 0.56
Chronic kidney disease (%) 6.1 (N=27,559) 5.9 (N=10,467) 6.2 (N=17,092) 0.85
Peripheral vascular disease (%) 6.55 (N=29,573) 8.4 (N=14,902) 5.3 (N=14,671) < 0.001
Heart failure (%) 41.7 (N=187,922) 49.3 (N=86,945) 36.8 (N=100,977) < 0.001
Coronary artery disease 
  (MI & Ischemic Heart Disease) (%) 65.1 (N=293,636) 72.7 (N=128,263) 60.2 (N=165,373) < 0.001
Diabetes mellitus (%) 19.8 (N=89,349) 21.2 (N=37,331) 18.9 (N=52,018) 0.03
Hypertension (%) 77.6 (N=349,993) 82.6 (N=145,837) 74.3 (N=204,156) < 0.001
Previous stroke /TIA (%) 5.8 (N= 26,195) 7.7 (N= 13,537) 4.6 (N=12,658) < 0.001
Previous systemic embolism (%) 1.3 (N=5,723) 2.1 (N=3,688) 0.7 (N=2,035) < 0.001
Thyrotoxicosis (%) 6.5 (N=29,470) 6.4 (N=11,331) 6.6 (N=18,139) 0.36
Previous major bleeding (%)  0.4 (N=7,601) 0.3 (N=4,375) 0.4 (N=3,226) 0.12
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Statistical Analysis
We estimated the risk of time to clinical end-
point using Cox proportional hazards regression, 
represented as hazard ratios (HR) with 95% con-
fidence intervals (CI). To the components of the 
CHADS2 and CHA2DS2VASc stroke risk scores, 
we included in the models, chronic obstructive 
pulmonary disease (COPD), chronic kidney dis-
ease (CKD) and hyperthyroidism/thyrotoxicosis 
– determined by a statistical significance level of 
5% and clinical consensus. Age was included, us-
ing categories 19 to 64 years, 65 to 74 years and 
≥75 years. Finally, the importance of age and sex 
was quantified by creating the categories male 
<65 years (as the reference), female <65 years, 
female >65 years and male >65 years. Data are 
demonstrated as mean ± standard deviation (SD) 
for normally distributed continuous variables, 
median (interquartile range, IQR) for skew-dis-
tributed continuous variables, and frequencies for 
categorical variables. 
The Hosmer-Lemeshow goodness of fit test 
(HLT) was used to assess the calibration of the 
models – whether the observed mortality rates 
matched the expected mortality rates in subgroups 
of 100 patients. A high HLT χ2 value and p-value 
<0.05 suggest a significant disagreement between 
observed and expected rates and therefore a poor 
model fit21. McFadden’s pseudo R2 was used to 
quantify the proportion of the variation in the da-
ta explained by the linear expression for the mean 
part of the model. A pseudo R2 <0.2 suggests a 
poor model fit, 0.2 to 0.4 a fair model fit and >0.4 
a good model fit22. The Brier score was used to 
measure the average squared deviation between 
the predicted probabilities of composite throm-
boembolism and the observed thromboembolism 
rates – the accuracy of the probability assessment. 
A Brier score of 1 suggests no accuracy, a score 
of 0 suggests perfect accuracy, and a score of 0.25 
suggests half the predicted events are correct and 
the other half not23. The C-statistic was used to 
evaluate the discriminative performance of the 
models. A C-statistic close to 1 suggests near-per-
fect discrimination and close to 0.5 almost no 
discrimination23. The increased discriminative 
value of CHA2DS2VASc over CHADS2 was ex-
amined with the net reclassification index (NRI) 
and the integrated discrimination improvement 
(IDI)23. The NRI was used to quantify the pro-
portion of patients moving up or down the 5-year 
thromboembolic joint endpoint risk categories of 
<5% (low), 5% to <10% (intermediate), and ≥10% 
(high) between the two models. These cut-points 
were based on formal decision analysis24. The IDI 
considers the change in the estimated prediction 
probabilities as a continuous rather than pre-spec-
ified categorical variable. Both schemes were di-
vided into low, moderate and high predicted risk 
categories. All analyses were conducted using 
Stata Version 11.0 (StataCorp, College Station, 
TX, USA). 
Results
Among the analytical cohort consisting 451,113 
patients, (mean age 66.1 ± 14.1 years, 56.1% fe-
male) 77.6% had hypertension, 41.7% heart fail-
ure, 19.8% diabetes and 5.8% a history of stroke or 
TIA. The analytical cohort represented 2,083,091 
patient-years of follow up, with a median time to 
censorship of 20 (IQR, 8 to 52) months and no sig-
nificant difference in median follow-up between 
on- and off-warfarin groups [18 (8 to 52) vs. 20 (10 
to 50) months, p=0.09]. In total, 274,631 (60.9%) 
had never been prescribed warfarin. Mode of the 
scores for CHA2DS2VASc (4 vs. 5) and CHADS2 
(2 vs. 3) were lower in the off-warfarin group com-
pared with those on-warfarin. Patients who were 
prescribed warfarin more frequently had a histo-
ry of peripheral vascular disease, heart failure, 
coronary artery disease, diabetes, hypertension, 
stroke, systemic embolism, and less frequently 
because of a previous hemorrhage (Table I). 
Risk Factors for Ischemic Stroke
On multivariable analysis, for patients who 
were off-warfarin the risk of thromboembolic 
endpoints increased with age (65 to 74 years: HR 
3.16, 95% CI 2.98 to 3.35; ≥75 years: 4.28, 4.05 
to 4.52, for the thromboembolic composite end-
point) (Table II). Significant independent associa-
tions were evident for prior ischemic stroke (HR 
2.45, 2.33 to 2.58), systemic embolism (HR 1.88, 
1.64 to 2.15), hypertension (HR 1.42,1.35 to 1.49), 
diabetes (HR 1.19, 1.14 to 1,24), females (HR 1.11, 
1.07 to 1.15), heart failure (HR 1.36, 1.31 to 1.40) 
and hyperthyroidism/thyrotoxicosis (HR 1.12, 
1.05 to 1.19). However, peripheral vascular dis-
ease, coronary artery disease, CKD and COPD 
were not significant risk factors for thromboem-
bolism. Females aged <65 years had a lower risk 
of thromboembolism than males <65 years (HR 
0.83, 95% CI 0.75 to 0.92), though there was a sig-
nificant increase in thromboembolic risk by age 
for females (females >65 years: 3.67, 3.40 to 3.95). 
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Table II. Associations between baseline factors and stroke and systemic embolism in patients without anticoagulant treatment (N = 274,631).
 Ischemic Stroke or Embolism Ischemic Stroke
Univariable Multivariable Univariable Multivariable
 Sig. HR
95,0% CI 
for HR Sig. HR
95,0% CI 
for HR Sig. HR
95,0% CI 
for HR Sig. HR
95,0% CI 
for HR
Lower Upper Lower Upper Lower Upper Lower Upper
COPD 0.00 1.46 1.41 1.51 0.98 1.00 0.96 1.04 0.00 1.46 1.41 1.52 0.84 1.00 0.96 1.04
Embolism 0.00 2.44 2.13 2.79 0.00 1.88 1.64 2.15 0.00 1.90 1.63 2.22 0.00 1.45 1.24 1.70
Chronic Renal Failure 0.00 1.47 1.38 1.56 0.61 1.02 0.96 1.08 0.00 1.40 1.32 1.50 0.41 0.97 0.91 1.04
Peripheral Arterial Disease 0.00 1.66 1.56 1.77 0.00 1.11 0.97 1.23 0.00 1.48 1.38 1.59 0.00 1.06 0.95 1.21
CHF 0.00 2.08 2.01 2.15 0.00 1.36 1.31 1.40 0.00 2.11 2.03 2.18 0.00 1.36 1.31 1.41
Ischemic Heart Disease 0.00 1.25 1.21 1.29 0.15 1.03 0.99 1.07 0.00 1.22 1.18 1.27 0.77 1.01 0.97 1.04
Myocardial Infarction 0.00 1.24 1.17 1.32 0.11 1.05 0.99 1.12 0.00 1.25 1.17 1.33 0.07 1.06 1.00 1.13
Diabetes 0.00 1.40 1.34 1.45 0.00 1.19 1.14 1.24 0.00 1.38 1.32 1.44 0.00 1.17 1.12 1.22
Hypertension 0.00 2.10 2.00 2.20 0.00 1.42 1.35 1.49 0.00 2.15 2.04 2.25 0.00 1.44 1.37 1.52
Ischemic Stroke 0.00 3.40 3.23 3.58 0.00 2.45 2.33 2.58 0.00 3.50 3.32 3.68 0.00 2.51 2.38 2.65
Thyroid Disease 0.00 1.16 1.09 1.24 0.00 1.12 1.05 1.19 0.00 1.17 1.09 1.25 0.00 1.12 1.04 1.19
Age <= 64* 0.00 ~ ~ ~ 0.00 ~ ~ ~ 0.00 ~ ~ ~ 0.00 ~ ~ ~
Age >= 65 & Age <= 74 0.00 3.86 3.65 4.09 0.00 3.16 2.98 3.35 0.00 4.12 3.88 4.38 0.00 3.36 3.16 3.58
Age >= 75 0.00 5.55 5.26 5.85 0.00 4.28 4.05 4.52 0.00 5.99 5.66 6.33 0.00 4.58 4.32 4.86
Gender = F^ 0.00 1.19 1.15 1.23 0.00 1.11 1.07 1.15 0.00 1.22 1.18 1.26 0.00 1.13 1.09 1.17
Gender = F & Age >= 65 0.00 5.62 5.23 6.04 0.00 4.36 4.06 4.70 0.00 5.92 5.49 6.38 0.00 4.56 4.23 4.93
p<0.05. *age range 19 to 64 years. ^females <65 years.
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Risk Score Performance
The CHADS2 and CHA2DS2VASc risk scores 
discriminated thromboembolic endpoints equally 
well (C-statistics both 0.73), and both had good ac-
curacy (Brier scores both 0.04). However, model 
fits were equally poor (HLT both p<0.001, pseu-
do R2 both <10%). For CHA2DS2VASc compared 
with CHADS2, the net reclassification index was 
6.9% (p<0.05) and integrated discrimination im-
provement was 3.7% (p<0.05) for the off-warfarin 
group. 
When we used the thromboembolic risk cut 
points derived from formal decision analysis, ac-
cording to the CHADS2 score there were 40,661 
(14.8%), 70,916 (25.8%) and 163,054 (59.4%) pa-
tients classified as low, intermediate and high 
risk, respectively. According to the CHA2DS-
2VASc score, there were 11,213 (4.1%), 27,563 
(10.0%) and 235,855 (85.9%) patients classified 
as low, intermediate and high risk, respective-
ly. The CHADS2 risk scheme reclassified 4,410 
(32.6%) high risk patients as low risk, and 16,320 
(6.2%) low risk patients as high risk (Supple-
mentary Table II). Equally, the CHA2DS2VASc 
risk scheme reclassified 4,321 (32.0%) high risk 
patients as low risk, and 25,234 (9.7%) low risk 
patients as high risk. Among patients off-warfa-
rin, the rates of thromboembolic and ischemic 
stroke increased with increasing CHADS2 and 
CHA2DS2VASc scores (Table III). Notably, for 
patients who did not receive warfarin, the rates of 
thromboembolism were low for those who were 
classified as low risk according to CHADS2 and 
low to intermediate risk by CHA2DS2VASc (0.34, 
0.55 and 0.68, respectively). 
Clinical Endpoints 
There were 29,448 off-warfarin patients and 
11,825 on-warfarin patients who had a CHADS2 
score of 0 and a CHA2DS2VASc score ≥1. For 
this group, the mean value of CHA2DS2VASc 
score was 1.32 (± 0.003) for those off-warfarin 
and 1.49 (± 0.006) for those on-warfarin. In this 
reclassified-high risk category compared with the 
off-warfarin subgroup, patients in the on-warfa-
rin subgroup were older (55.5 ± 12.6 vs. 48.9±15.4 
years, p<0.005), and more frequently had CKD 
(3.1% vs. 1.2%), COPD 16.7 % vs. 7.4%), male 
gender (38.7% vs. 31.8%). 
Among reclassified-high risk category, in the 
off-warfarin subgroup, 290 patients (0.98%) had 
a thromboembolic endpoint and 179 (0.61%) had 
a major hemorrhage, whereas in the on-warfarin 
subgroup, 354 patients (3.0%) had a major hem-
orrhage and 112 patients (0.94%) had a thrombo-
embolic endpoint. At 1 year, mortality and hospi-
talization rates were 4.1% (1222) and 2.0% (575 
patients) for the off-warfarin subgroup and 2.7% 
(318 patients) and 13.5% (1591 patients) for the 
on-warfarin subgroup (p<0.005 for both param-
eters). 
In reclassified high-risk category, NCB (-0.035) 
and UNCB (-0.021) were negative and there was 
harm with oral anticoagulation in this catego-
ry. In remaining patients with OAC indication 
(CHADS2 > 1 and CHA2DS2VASc score >1 for 
man and CHA2DS2VASc score >2 for woman), 
treatment was beneficial and NCB (0.004) and 
UNCB (0.039) were higher than reclassified high-
risk category (p<0.001 for both parameters). 
Discussion
The main findings of the present study are 
as follows: (i) in reclassified-high risk category 
(patients with a CHA2DS2VASc score of ≥1 and 
CHADS2 score of 0), the rate of major hemorrhage 
for those prescribed warfarin was significant and 
much higher than the rate of thromboembolism 
among those who did not receive warfarin, (ii) 
NCB (-0.035) and UNCB (-0.021) were negative 
and there was harm with oral anticoagulation 
in this category, (iii) rates of death and hospi-
talization at 1 year were significantly higher for 
on-warfarin group.
Stroke risk stratification schemes, such as 
CHA2DS2VASc and previously CHADS2 classi-
fy patients to different risk groups9,10,25-27. Among 
these 2 scores, CHA2DS2VASc significantly re-
classified about 7% of patients, there was evidence 
for movement of large numbers of patients up and 
down risk cut-offs for both risk scores. Each risk 
score defined approximately one-third of high risk 
as low risk. We found the risk scores, endorsed 
by international guidelines, had similar discrim-
inatory performance and equally poor goodness 
of fit when assessed according to a variety of in-
dices. The uncertainty around the estimation of 
outcomes among the reclassified-high risk cate-
gory (with a CHA2DS2VASc ≥1 and CHADS2 = 0) 
resulted with one-fifth of patients with non-valvu-
lar AF being prescribed warfarin of whom 3.0% 
had a major hemorrhage and 0.9% of the remain-
ing off-warfarin group having a thromboembolic 
event at a median follow-up of about one and a 
half years. Even though the CHA2DS2VASc score 
is superior at identifying patients at a lower risk 
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of thromboembolism10, CHA2DS2VASc score can 
overestimate the risk of the low risk patients as-
sessed by CHADS2. Importantly, the decision to 
not prescribe an OAC resulted in a lower than ex-
pected stroke rate (0.9% composite thromboem-
bolic event rate at median 20 months in TRAF 
vs. 1.3%-year stroke rate for CHA2DS2VASc ≥1)
28. 
There are many studies favoring the use of the 
CHA2DS2VASc to identify patients at low risk 
of stroke29-34. Recent data and current guidelines 
suggest OAC to prevent thromboembolism in 
male AF patients with a CHA2DS2-VASc score 
of 1 and in female AF patients with a CHA2DS2-
VASc score1,35. We found that not all of the factors 
used in the CHA2DS2VASc score carried equal 
risk. The strongest predictors were age, followed 
by previous stroke, previous systemic emboli, hy-
pertension, heart failure, diabetes, hyperthyroid-
ism/thyrotoxicosis, and female; whereas periph-
eral vascular disease (as well as chronic kidney 
disease, and COPD) were not significant indepen-
dent predictors. The lack of association between 
stroke and coronary artery or peripheral artery 
disease is consistent with the conclusions from 
the ATRIA study36 and ROCKET AF subgroup 
analysis37. However, our finding of no association 
between stroke and renal failure was inconsistent 
with some36,38, but not all studies20.
Uncertainty around the optimal method to 
estimate stroke risk in low-to-intermediate risk 
patients with non-valvular AF is not new. Many 
studies have debated the strengths and weakness-
es of the CHADS2 and CHA2DS2VASc scores. For 
example, data from the ATRIA study36 suggest 
that the categorized CHADS2 score is a better pre-
dictor of composite thromboembolism than cate-
gorized CHA2DS2VASc, whereas other studies 
support the use of the CHA2DS2VASc score
29,34,39. 
This, in the context of the findings from our study, 
suggests that the recommendation for an OAC 
among reclassified-high risk category (CHA2DS-
2VASc ≥1 and CHADS2 =0) patients with non-val-
vular AF, is based upon a careful discussion about 
the pros and cons of an OAC with the patient until 
an optimal score is devised. International guide-
lines recommend the use of the CHADS2 score to 
rule in warfarin for patients with a score of 2, and 
the CHA2DS2VASc score as a more detailed risk 
CHADS2 classification Ischemic stroke
Ischemic Stroke/TIA/Systemic 
Embolism
Score Risk  categories % n Total population % n Total population %
0 Low 14.81 277 40661 0.68 336 40661 0.83
1 Intermediate 25.82 1342 70916 1.89 1500 70916 2.12
2 2486 66787 3.72 2710 66787 4.06
3 2821 51211 5.51 2996 51211 5.85
4 High 59.37 2739 25198 10.87 2831 25198 11.24
5 2441 16093 15.17 2507 16093 15.58
6 587 3765 15.59 609 3765 16.18





categories % n Total population % n Total population %
0 Low 4.08 38 11213 0.34 46 11213 0.41
1 Intermediate 10.04 151 27563 0.55 188 27563 0.68
2 539 38413 1.40 620 38413 1.61
3 1220 47202 2.58 1353 47202 2.87
4 2049 49215 4.16 2204 49215 4.48
5 High 85.88 2471 44171 5.59 2625 44171 5.94
6 2503 30306 8.26 2609 30306 8.61
7 2114 16503 12.81 2185 16503 13.24
8 1302 8108 16.06 1343 8108 16.56
9 306 1937 15.80 316 1937 16.31
Total 12693 274631 4.62 13489 274631 4.91
Table III. Stroke or thromboembolism at risk in relation to CHADS2 and CHA2DS2-VASc scores in 274,631 patients without 
warfarin throughout follow-up.
Harm of anticoagulation in reclassified high-risk category
11219
factor approach for those with a CHADS2 score 
of 1 or 22. Results from our study emphasize the 
need for comprehensive risk factor review which 
includes that of a patient’s bleeding risk. 
Strengths and Limitations of the Study
The TRAF registry is the largest whole country 
database of patients with AF that has complete as-
certainment for stroke, embolic and hemorrhagic 
outcomes. Up to the time of identification of the 
sampling frame, the only OAC in use in Turkey 
was warfarin – thereby allowing an informative 
analysis of the impact of its use by stroke risk 
score in consecutive patients with non-valvular 
AF. Our data was linked to healthcare utilization, 
prescribing and outcomes data which enabled the 
accurate estimation of on- and off-warfarin risk 
of thromboembolic and hemorrhagic events in a 
large and generalizable subset of patients. Howev-
er, our study has limitations. Owing to its design 
there will be systematic bias such as that from the 
erroneous recall of a patient’s history, prescrip-
tion recording inaccuracies, misclassification of 
endpoints and under-reporting of events which 
did not reach the attention of medical services. 
Specifically, we were not able to validate the jus-
tification for ineligibility to receive care as this in-
formation was not sensitive enough – so for some 
patients it may have been appropriate to withhold 
specific interventions. We were only able to iden-
tify death from all-causes and the assumption 
was that deaths not related to AF or its thrombo-
prophylaxis management were equally balanced 
between groups. Baseline risk was assessed, and 
outcomes were noted during the 5-year study pe-
riod. However, risk does not remain static. There 
was no data regarding time in therapeutic range 
which estimates the percentage of time a patient’s 
INR is within the desired treatment range and is 
widely used as an indicator of anticoagulation 
control. Information about antiplatelet medication 
using status was absent. Finally, we did not con-
sider novel oral anticoagulants, which have lower 
risks of hemorrhage, and therefore may have re-
duced the on-OAC rates of harm to favor of the 
use of the CHA2DS2VASc score. 
Conclusions
Imprecision of stroke risk assessment among 
patients with a reclassified-high risk category re-
sulted in the prescription of warfarin to one-fifth 
of patients of whom 3% had a major hemorrhage 
and only 0.9% of those off-warfarin having a 
thromboembolic event at 20 months. There was 
harm with oral anticoagulation in this category, 
net clinical benefit indices are negative; rates of 
death and hospitalization at 1 year were signifi-
cantly higher for on-warfarin group. Whilst newer 
OAC may help alleviate this problem, our results 
emphasize the importance of greater attention to 
balancing the risks and benefits of OAC therapy 
in low-to-intermediate risk patients with non-val-
vular AF. 
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